| 000 | 01572 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517162724.0 | ||
| 264 | 0 | _c20180705 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1439-7609 | ||
| 024 | 7 |
_a10.1080/14397595.2017.1337056 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTanaka, Yoshiya | |
| 245 | 0 | 0 |
_aSafety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bModern rheumatology _cJan 2018 |
||
| 300 |
_a58-65 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 |
_aChemokine CX3CL1 _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 700 | 1 | _aTakeuchi, Tsutomu | |
| 700 | 1 | _aUmehara, Hisanori | |
| 700 | 1 | _aNanki, Toshihiro | |
| 700 | 1 | _aYasuda, Nobuyuki | |
| 700 | 1 | _aTago, Fumitoshi | |
| 700 | 1 | _aKawakubo, Makoto | |
| 700 | 1 | _aKitahara, Yasumi | |
| 700 | 1 | _aHojo, Seiichiro | |
| 700 | 1 | _aKawano, Tetsu | |
| 700 | 1 | _aImai, Toshio | |
| 773 | 0 |
_tModern rheumatology _gvol. 28 _gno. 1 _gp. 58-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14397595.2017.1337056 _zAvailable from publisher's website |
| 999 |
_c27342372 _d27342372 |
||